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Following immunogenic challenge, infiltrating and dividing lymphocytes 
significantly increase lymph node (LN) cellularity leading to organ expansion1,2. 
Here we report that the physical elasticity of LNs is maintained in part by 
podoplanin (PDPN) signalling in stromal fibroblastic reticular cells (FRCs) and 
its modulation by CLEC-2 expressed on dendritic cells (DCs). We show that 
PDPN induces actomyosin contractility in FRCs via activation of RhoA/C and 
downstream Rho-kinase. Engagement by CLEC-2 causes PDPN clustering and 
rapidly uncouples PDPN from RhoA/C activation, relaxing the actomyosin 
cytoskeleton and permitting FRC stretching. Notably, administration of CLEC-2 
protein to immunised mice augments LN expansion. In contrast, the latter is 
significantly constrained in mice selectively lacking CLEC-2 expression in 
DCs. Thus, the same DCs that initiate immunity by presenting antigens to T 
lymphocytes3 also initiate remodeling of LNs by delivering CLEC-2 to FRCs. 
CLEC-2 modulation of PDPN signalling permits FRC network stretching and 
allows for the rapid LN expansion driven by lymphocyte influx and proliferation 
that is the critical hallmark of adaptive immunity. 
LNs are meeting places for T lymphocytes and antigen presenting DCs1,2. T cell - DC 
interactions are supported by FRCs4,5, a complex interconnected network that 
produces and ensheathes extracellular matrix components6 that filter draining 
lymph7. FRC networks additionally provide physical routes for leucocyte traffic1, and 
chemoattractants for T cells and DCs5. Additionally, contact with FRCs promotes 
chemokinesis in DCs facilitating their migration within LNs8. This is partly due to 
cytoskeletal changes in DCs induced upon signalling by the C-type lectin receptor 
CLEC-2 when it is engaged by PDPN expressed on FRCs8. Here, we asked whether, 
in addition to promoting DC movement along FRCs, CLEC-2 might also work in 
reverse, modulating PDPN function and altering the properties of the FRC network. 
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To examine PDPN signalling in fibroblasts, wild-type (WT) PDPN tagged with CFP 
(PDPN-CFP) was over-expressed in NIH/3T3 cells, which express only low levels of 
the endogenous protein8. Within 30h of transfection, CFP was detectable at the 
plasma membrane where it co-localised with Cherry-tagged ezrin, consistent with 
reports of a direct interaction between the two proteins9,10 (Fig. 1a, Extended Data 
Video 1). Ezrin belongs to the family of closely related proteins, ezrin, radixin and 
moesin (ERM), which tether the actin cytoskeleton to the plasma membrane. We 
therefore examined localisation and phosphorylation of ERM proteins, along with 
myosin light chain (MLC), which mediates actin-dependent contraction, in PDPN-
CFP overexpressing cells. In contrast to untransfected cells, PDPN-CFP+ NIH/3T3 
cells displayed pERM and pMLC accumulation at the cell cortex (Fig. 1a) and often 
rounded up, features typical of contractile cells11-14. A non-phosphorylatable ezrin 
T567A mutant formally demonstrated the key role of ERM phosphorylation in PDPN-
driven cell contraction (Fig. 1b).  
To determine which pathways connected PDPN to cell contraction, a chemical 
screen was conducted, which revealed relaxation upon inhibition of RhoA/C, ROCK, 
or Myosin II (Extended data Fig. 1a, b). Strikingly, treatment with soluble recombinant 
CLEC-2-Fc protein phenocopied RhoA/C and ROCK inhibition, almost completely 
reversing the contraction induced by PDPN-CFP (Fig. 1c). The inhibition by CLEC-2 
was rapid but transient (Fig. 1c) and led to ezrin re-distribution from the plasma 
membrane to the cytoplasm (Fig. 1d). To test this in FRCs expressing physiological 
levels of PDPN, we generated LN FRC lines (Extended Data Fig. 2 and Methods). 
Sub-lines stably expressing FRET biosensors reporting RhoA or Rac1 activity were 
exposed to CLEC-2-Fc-coated 10 μm beads. In agreement with the NIH/3T3 studies, 
RhoA activity was immediately and robustly reduced when CLEC-2-beads made 
contact with FRCs (Fig. 1e and Extended Data Video 2). Sudden loss of RhoA 
activity was also evident from temporary loss of adhesion15 (Extended Data Videos 2 
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and 3). In contrast, Rac1 activity gradually increased after exposure to CLEC-2 
beads (Fig. 1e, and Extended Data Video 3), which was confirmed in longer-term 
experiments by pulldown of GTP-bound Rac1 (Fig 1f). Higher Rac1-GTP levels, 
increased ARP2/3+ lamelipodial protrusions and tail retraction defects were also 
observed in FRCs when PDPN was stably depleted (PDPN KD FRCs; Fig. 1f and 
Extended data Fig. 3). To identify guanine-nucleotide exchange factors (GEFs) that 
may connect PDPN to activation of RhoA/C, we decreased expression of candidates 
using siRNA and found that PDPN-induced contractility primarily requires GEF-H1 in 
NIH/3T3 and FRCs (Extended data Fig. 1c, d). We also looked for further changes in 
FRCs consistent with decreased RhoA/C activity and found that PDPN knockdown or 
engagement by CLEC-2 caused rapid dissolution of stress fibres (Fig. 1g, Extended 
Data Video 4, Extended data Figs. 3, 4). Thus, PDPN in fibroblasts associates with 
ezrin and signals to promote RhoA/C-dependent actomyosin-driven contraction. This 
is alleviated by CLEC-2 engagement, causing uncoupling of PDPN from ezrin and a 
RhoA/C to Rac1 switch. We hypothesise that Rac1 activity is increased indirectly as 
a consequence of reduced RhoA/C activity14,16. 
The cytoplasmic tail of PDPN undergoes phosphorylation and ezrin recruitment 
requires basic residues surrounding serine 167 (S167) 10,17.  We therefore tested 
whether phosphorylation of S167 controlled PDPN-induced contractility. Over-
expression of PDPN (S167A) mutant failed to cause contraction in NIH/3T3 
fibroblasts and occasionally caused collapse of the cytoskeleton, potentially by 
inhibiting activity of low levels of endogenous PDPN (Fig. 2a). In contrast, a PDPN 
S167E phosphomimetic mutant induced contractility comparable to WT protein (Fig. 
2a, b). Inhibition of ROCK blocked contraction by both WT and S167E PDPN (Fig. 
2b), placing ROCK activity downstream of S167 phosphorylation. However, CLEC-2-
Fc treatment, whilst inhibiting contraction induced by WT PDPN, had no effect on 
S167E PDPN (Fig. 2b), suggesting that regulation of the phosphorylation status of 
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S167 is one mechanism by which CLEC-2 uncouples PDPN from actomyosin 
contractility. 
We considered how FRCs express high levels of endogenous PDPN yet, unlike 
transfected NIH/3T3 cells, do not display hypercontractility. As PDPN remained at 
the plasma membrane when engaged with CLEC-2 (Fig. 1d), we hypothesised that it 
partitions between active and inactive pools, the latter being maintained by binding to 
an inhibitory partner such as CD4418,19. FRCs express high levels of both PDPN and 
CD444 and knockdown of PDPN led to a concordant reduction of CD44 (Fig. 2c), 
suggesting an interaction. NIH/3T3 express low levels of CD44, perhaps accounting 
for their susceptibility to contract following PDPN overexpression. Consistent with 
that notion, co-transfection of CD44 and PDPN into NIH/3T3 fibroblasts markedly 
inhibited contraction (Fig. 2d). 
CD44 resides within cholesterol-rich lipid rafts19 and we tested whether CLEC-2 
induces PDPN redistribution to such rafts. In steady state FRCs, PDPN and lipid rafts 
were found in small, partial colocalised clusters (Fig. 2e), as described in epithelial 
cells20. CLEC-2-Fc treatment induced formation of larger clusters in which PDPN and 
lipid rafts were more often colocalised (Fig. 2e). Notably, depletion of cholesterol 
from FRC membranes with methyl-β-cyclodextrin (MβCD) increased contractility, 
which was prevented by PDPN knockdown (Fig. 2f). CLEC-2 no longer inhibited 
PDPN-induced contraction in NIH/3T3 pre-treated with MβCD (Fig. 2g). Together, 
these data support the notion that CLEC-2 sequesters PDPN within lipid rafts, where 
increased interaction with CD44 prevents signalling to RhoA/C. Interestingly, CD44 
can itself also drive contractility when excluded from lipid rafts (data not shown) 
suggesting a mutually inhibitory interaction with PDPN. 
To explore the biological significance of PDPN/CLEC-2 interactions for FRC function, 
we examined cell behaviour in 3D collagen gels. Notably, FRCs reorganised the gel 
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matrix to occupy a smaller volume and this was inhibited by CLEC-2 treatment or 
PDPN knockdown (Fig. 3a). Furthermore, CLEC-2 treatment or PDPN knockdown 
caused marked elongation of FRCs in 3D culture (Fig. 3b, Extended data Fig. 5). To 
determine the relevance of FRC stretching for LN dynamics, we investigated FRC 
network changes following induction of inflammation in vivo, which leads to 
upregulation of CLEC-2 by both LN resident and migratory DCs8,21.  We first 
examined the cellular composition of draining LNs after subcutaneous immunisation 
of mice with ovalbumin (OVA) in complete Freund’s adjuvant (CFA). During the 
afferent phase (days 0-6), T and B cell numbers increased rapidly and total LN 
cellularity augmented 2-3 fold (Extended data Fig. 6). However, numbers of FRCs 
(CD45- PDPN+ CD31-) remained constant until day 6 (Fig. 3c). This lag in FRC 
proliferation has been previously observed22 although the kinetics likely depend on 
the type and strength of the inflammatory stimulus. In contrast, blood endothelial 
cells (BECs; CD45- PDPN- CD31+), a distinct LN stromal population, increased in 
number from the earliest timepoint (Extended data Fig. 6). 
If FRCs do not proliferate during early stages of acute inflammation, then to 
accommodate increased LN size the FRC network needs to ‘stretch’ to avoid 
disruption22. Consistent with that, the mean forward scatter of LN FRCs, an indication 
of cell size, increased after immunisation (Fig. 3d)22 despite no loss of integrity of the 
FRC network (Fig. 3e). A gap analysis algorithm23 revealed significantly larger 
spaces between the reticular network branches after immunisation, consistent with 
FRC stretching (Fig. f). In a complementary approach, we utilised PDGRFaKI-H2B-
GFP mice (Extended data Fig. 7) and calculated the spacing between FRC nuclei 
(GFP+) using automated morphometric analysis software, which confirmed that FRCs 
spread further apart after immunisation (Fig. 3g). Together, these data indicate that 
FRCs expand and that the pre-existing FRC network enlarges in response to acute 
inflammation such as following immunisation. 
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The profound cytoskeletal changes in FRCs following CLEC-2 binding in vitro, 
suggested that inhibition of PDPN-induced contractility by CLEC-2+ DCs might aid 
FRC network enlargement in vivo. Consistent with this, LN influx of immigrant DC 
(CD45+, CD11c+, MHCIIhi) bearing high CLEC-2 levels8 peaked at day 2 post 
OVA/CFA immunisation (Fig. 3c). We therefore examined LN architecture and 
expansion in CD11cCre x Clec1bloxP/loxP mice (CD11cΔCLEC-2). These mice display 
selective ablation of CLEC-2 in CD11c+ cells (Extended data Fig. 8), the majority of 
which within the T cell zone are DCs. Interestingly, in >24 week old CD11cΔCLEC-2 
mice, steady state LN size was significantly reduced compared to controls (Fig 4a), 
which was not the case in younger mice (Fig. 4b; non-draining LN). However, 
following immunisation, expansion of draining LNs was attenuated and spaces within 
the FRC network were smaller in young CD11cΔCLEC-2 mice compared to controls 
(Fig. 4b, c). Finally, LNs of CD11cΔCLEC-2 mice remained more rigid and less 
deformable than controls following immunisation (Fig 4d).  
Attenuated expansion of LNs in CD11cΔCLEC-2 mice could be due to reduced numbers 
of immigrating DCs, reducing antigen availability and limiting T cell expansion. 
However, similar results were obtained upon administration of incomplete Freund’s 
adjuvant without OVA or mycobacterial antigens (data not shown). Moreover, 
treatment by subcutaneous injection of recombinant CLEC-2-Fc protein but not a 
control Fc reagent (data not shown) following CFA/OVA immunisation markedly 
augmented LN expansion (Fig. 4e) and, importantly, completely rescued defects in 
LN expansion in CD11cΔCLEC-2 mice (Fig 4e). The latter result indicates that 
diminished CLEC-2 provision rather than a dearth of immigrant antigen-presenting 
DCs limits LN expansion in CD11cΔCLEC-2 mice. In sum, these data suggest that 
CLEC-2 delivery by DCs is required for maintaining FRC network architecture in vivo 
and is permissive for acute increases in LN size driven by cell influx provoked by 
local inflammation. 
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LNs are dynamic structures that must rapidly expand to accommodate leucocyte 
recruitment and proliferation. Given that LNs can expand 10-fold during adaptive 
immune responses while maintaining integrity, stromal components must by 
necessity proliferate22,24. However, in early phases of adaptive immune responses or 
in response to acute inflammation, FRC proliferation is insufficient to account for 
lymph node expansion (Fig. 3b and 22). Here, we show that early LN expansion is 
permitted by FRC network relaxation, induced by increased availability of CLEC-2hi 
DCs. We previously reported that CLEC-2 engagement by PDPN promotes DC 
migration along the FRC network8. Our data now show that PDPN is not simply a 
ligand for CLEC-2 but that it also reverse signals into FRCs to control actomyosin 
contractility. Our results suggest that a function of endogenous PDPN on FRCs is to 
cause stromal network contraction and create physical tension in LNs. This is offset 
by constant contact between FRCs and CLEC2+ resident DCs, balancing contractility 
and controling LN cellularity. The influx of additional CLEC-2hi DCs, combined with 
the upregulation of CLEC-2 on resident DCs during acute inflammation8, increases 
inhibition of PDPN, allowing the FRC network to stretch. We predict that this same 
mechanism can promote LN reduction as the short wave of increased CLEC-2 
availability ends and PDPN activity returns. Whether the underlying collagen network 
is similarly elastic and to what extent acts to limit or promote LN expansion is as-yet 
unaddressed. Interestingly, CLEC-2 is not sufficient for LN expansion as 
administration of CLEC-2-Fc in the absence of inflammation did not affect LN size. 
Rather, CLEC-2 inhibition of PDPN is permissive for stretching and the influx of 
leucocytes via the HEV and afferent lymph likely provides the force for expansion. It 
is interesting to speculate that the stretching mechanism described in this study may 
also help initiate subsequent FRC proliferation given the emerging connections 
between tension and cell cycle regulation25.  
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Figure Legends. 
Figure 1. CLEC-2 binding uncouples PDPN from RhoA/C- and actomyosin-
driven fibroblast contractility. a) NIH/3T3 expressing PDPN-CFP (blue) or 
untransfected (control), fixed and stained for pERM (green) or pMLC (S19) (green) 
and F-actin (red). Scale bar 20 μm. b) Frequency of contracting NIH/3T3 expressing 
PDPN-cherry or PDPN-cherry and Ezrin T567A-GFP. c) NIH/3T3 expressing PDPN-
CFP (green) stained F-actin (red) treated with 10 μg/ml CLEC-2-Fc (15 min). Scale 
bar 50 μm. Quantification in the right panel depicts mean ± SD of 3 experiments 
(>300 cells). Fisher’s exact test (****, p< 0.00005, ***, p< 0.0005). d) NIH/3T3 
expressing PDPN-CFP and Ezrin-mCherry treated with 10 μg/ml CLEC-2-Fc (15 
min). Single optical slice (1 μm), scale bar 20 μm. Pixel colocalisation analysis is 
shown at bottom. e) FRC cell lines expressing RhoA or Rac1 FRET biosensors 
exposed to CLEC-2-Fc-coated beads. Quantification of FRET ratio is shown on right 
and depicts mean ± SD of 15 cells from 2 independent experiments. f) Left: total and 
GTP-bound Rac-1 in lysates from FRCs treated with 10 μg/ml CLEC-2-Fc (30 min). 
Right: same analysis in two independent PDPN-knockdown FRC lines (KD1 and 
KD2) vs. control line. g) FRC cell lines expressing GFP-MLC (grayscale) treated with 
CLEC-2-Fc-coated beads.  
Figure 2. CLEC-2 binding causes redistribution of PDPN within the plasma 
membrane. a) NIH/3T3 expressing V5 tagged-PDPN mutants (PDPN-V5) stained for 
V5 (green) and F-actin (red). Scale bar 50 μm. b) Contraction score of NIH/3T3 
expressing WT or mutant PDPN treated with 10 μM ROCK inhibitor (Y27632) (6 
hours) or 10 μg/ml CLEC-2-Fc (30 min). Mean ± SD of 3 independent experiments 
(>300 cells). Fisher’s exact test (****, p<0.00005). c) Surface expression of PDPN 
and CD44 in the indicated cells as analysed by flow cytometry d) Contraction score 
of NIH/3T3 expressing PDPN-V5 ± CD44-GFP. Mean ± SD of 3 experiments (>150 
cells). Fisher’s exact test (p<0.05).  e) Confocal slices (0.5 μm) showing surface 
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staining of lipid rafts and PDPN on primary FRCs treated with 10 μg/ml CLEC-2-Fc 
protein (45 min). Scale bar 50 μm. Colocalisation correlation coefficient R is shown 
on right; each point represents one cell. Mann Whitney U test (****, p<0.0001). f) 
Left: FRC cell lines treated with 250 μM MβCD (6 hours) stained for F-actin (red) and 
DNA (blue). Scale bar 50 μm. Right: contraction score in the indicated FRC cell lines 
treated with MβCD. Mean ± SD of 3 experiments >300 cells. Fisher’s exact test (****, 
p< 0.00005). g) Contraction score in PDPN-CFP-expressing NIH/3T3 pretreated with 
250 μM MβCD (6 hours) and subsequently treated with 10 μg/ml CLEC-2-Fc (15 
min). Mean ± SD of 3 experiments (>300 cells). Fisher’s exact test (****, p< 0.00005). 
Figure 3. The FRC network stretches to accommodate acute increases in LN 
cellularity. a) Collagen matrix contraction by FRC cell lines treated with 10 μg/ml 
CLEC-2-Fc, anti-PDPN antibody or stably depleted of PDPN. Representative image 
is shown above. Mean ± SD 8 replicates from 2 experiments. 1-way ANOVA, 
Dunnetts multiple comparisons (***, p<0.0001, ****, p<0.00001) b) Maximum 3-
dimensional length from cells as in (a) calculated from 100 μm confocal z-stacks. 
Graphs indicate median, 25th and 75th percentiles (Range 10-90 percentile). 2 
independent experiments (>80 cells). 1-way ANOVA, Dunnetts multiple comparisons 
(*, p<0.05, ****, p<0.00001). c) LN mass, number of migratory DCs (CD45+ CD11c+ 
MHCIIhi) and number of FRCs (CD45- PDPN+ CD31-) in LNs draining the site of 
OVA/CFA immunisation. Each point represents one LN. Mean ± SD 2 experiments 
with 8-12 mice per timepoint. Day 0 represents non-immunised mice. 1-way ANOVA, 
Tukey’s multiple comparisons (*, p<0.05, **, p>0.001, ***, p>0.0001, ****, 
p<0.00001).    d) Forward scatter of FRCs following OVA/CFA immunisation (day 6). 
Mann Whitney U test (**, p< 0.001). e) ER-TR7 staining (green) of the T cell zone of 
draining or non-draining LNs following OVA/CFA immunisation (day 6). Scale bar 30 
μm. f) Left: PDPN staining (white) of LN sections as in (e) converted to binary 
images for gap analysis. Scale bar 100 μm. Right: Gaps (coloured circles) within the 
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FRC network. White box = area at higher magnification. Quantification  is shown on 
far right. p = 4.194e-09 (proportion of radii> 15 μm), Fisher’s exact test. g) 
Morphometric analysis of GFP+ nuclei (FRCs) in draining or non-draining LN sections 
from PDGFRaKI-H2B-GFP mice following CFA/OVA immunisation (day 6) (left). anti-
GFP (brown), hematoxylin (blue). Quantification of average area occupied by 
individual FRCs is shown on right. Data in f and g are from multiple sections from 8 
mice in 2 independent experiments. Mann Whitney U test (****, p< 0.00001). 
Figure 4. CLEC-2+ dendritic cells are required for LN swelling during adaptive 
immune responses. a) Mass of skin draining LNs from CD11cΔCLEC-2 mice and 
Creneg littermate controls, >24 weeks old. Data are normalised to average LN mass of 
Creneg control. Each data point represents 1 LN. Mann Whitney U test (****, p< 
0.00001). b) LN mass (mg) of draining and non-draining LNs from 8-12 week old 
CD11cΔCLEC-2 mice and Creneg littermates (control) immunised with OVA/CFA (day 7). 
Each point represents a LN. Data from 3 experiments. 2-way ANOVA, Tukey’s 
multiple comparisons (**, p< 0.001). c) Gap analysis of draining LNs from immunised 
control (top) and CD11cΔCLEC-2 mice (bottom), quantified on the right. p = 0.0001759 
(radii> 8 μm), Fisher’s exact test. d) LN deformation following compression of whole 
LNs with 1.4N force. Each point represents one LN. p<0.05, 1-way ANOVA. e) LN 
mass of CD11cΔCLEC-2 mice and Creneg littermates (control) 7 days following CFA/OVA 
immunisation and treatment with 10 μg CLEC-2-Fc or PBS (days 1 and 3). Each 
point represents one LN, data from 3 experiments. 2-way ANOVA, Tukey’s multiple 
comparisons test (**, p< 0.001; ***, p< 0.0001; n.s., non-significant).  
Extended data Figure 1. Screen for inhibitors of PDPN-mediated cell 
contractility. a) Quantification of proportion of contracted NIH/3T3 fibroblasts 
expressing eGFP control or PDPN-CFP and treated with the indicated inhibitors or 
vehicles. Statistically significant inhibition: **** p <0.00001 and * p = 0.01, Fisher’s 
Exact test. Data represent mean ± SD of 3 independent experiments. b) Chemical 
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inhibitors used in (a) and their targets. c) Contraction score of PDPN-expressing 
NIH/3T3 fibroblasts transfected with siRNA smartpools targetting the indicated Rho 
GEFs (MU-046870-01-0002, MU-040120-00-0002, MU-047092-01-0002, MU-
041056-01-0002, Dharmacon, GE Healthcare). **, p<0.05, one-way ANOVA. d) 
Maximum length of FRCs in collagen gels measured in 3-dimensions from 100 μm 
deep confocal z-stacks. Each point represents one FRC. **, p<0.05, one-way 
ANOVA. e) PCR analysis of RhoGEF mRNA expression in FRC cell lines following 
siRNA knockdown in comparison to expression of GAPDH.  
Extended data Figure 2. Generation of FRC lines. Comparison of an FRC cell line 
generated by immortalisation of primary FRCs (bottom panels, blue) with primary 
FRCs in LN cell suspensions cultured for 7 days (top panels, red). Gray histograms 
indicate isotype-matched control antibody staining. Histograms of primary LN 
cultures are gated on CD45- CD140a+ cells to exclude haematopoietic cells and other 
stromal subsets. Histograms of the FRC cell line are gated only on live cells. 
Extended data Figure 3. Loss of PDPN results in FRC spreading and actin 
polymerisation. a) Single optical slice (1 μm) showing morphology and pMLC 
organisation of control and PDPN KD FRCs. pMLC S(19) (green), F-actin (red). 
Scale bar indicates 50 μm b) Quantification of the number of ARP2/3 positive 
protrusions per FRC comparing control (green) and PDPN KD (red) cell lines. Data 
represent mean +/-SD, each point represents an individual FRC. p<0.0001 
calculated using Mann Whitney U test. c) Quantification of tail retraction defects 
comparing control and PDPN KD FRCs. Data are collated from >100 cells, p<0.0001 
calculated using Fisher’s exact test. “Present” means that tail retraction defects were 
deemed present by the observer. 
Extended data Figure 4. Loss of pMLC and F-actin filaments following 
treatment of FRCs with CLEC-2. Single optical slices (1 μm) of FRC cell lines 
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treated for 30 min with 10 μg/ml soluble CLEC-2-Fc protein, fixed and stained for 
pMLC (S19) (green) and F-actin (red). Scale bar represents 50 μm. Higher 
magnification shown in right hand panels. Scale bar represents 5 μm.   
Extended data Figure 5. Elongated morphology of CLEC-2-treated FRCs in 3D 
cultures. Quantification of maximum cell length for 100 μm deep z-stacks. FRCs 
cultured in 3D collagen/matrigel matrix for 3 days treated with CLEC-2-Fc, ROCK 
inhibitor 10 μM (Y27632), or stably knocked down for PDPN expression. Left panel 
shows projection of the 3D stack; staining F-actin (red), DNA (cell nuclei, blue). Scale 
bar indicates 200 μm. Centre panel shows x,y,z coordinates and length of each 
vector for each end of each cell in 3D as quantified using Imaris image analysis 
software. Right panel shows example of cell morphology in each treatment group; 
staining F-actin (red), DNA (cell nuclei, blue). Scale bar indicates 50 μm. 
Extended data Figure 6. Timecourse of LN expansion following OVA/CFA 
immunisation. Total cellularity, number of T cells (CD45+, CD3+), B cells (CD45+, 
CD19+) and BEC (CD45- PDPN- CD31+) in draining LNs at different times after 
OVA/CFA immunisation. Each point represents one lymph node and data show 
mean ± SD of 2 independent experiments scoring 8-12 mice. Day 0 represents LNs 
from non-immunised mice. Asterisks represent statistically significant differences 
between non-immunised and immunised mice as calculated using 1-way ANOVA 
test followed by Tukey’s multiple comparisons test (*, p<0.05, **, p>0.001, ***, 
p>0.0001, ****, p<0.00001).     
Extended data Figure 7. FRCs are selectively labelled in PDGFRαKI H2B-GFP 
mice. a) Analysis of skin draining LNs from PDGFRαKI H2B-GFP mice showing 
lymph node stromal cells co-expressing CD140a (PDGFRa) and GFP. Left panel 
shows gate for CD45- stroma, right panel shows GFP and CD140a expression of 
CD45- gate. b) Flow cytometry analysis showing that GFP+ cells are CD140a+. Left 
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panel shows gating for GFP+ LN cells, right panel shows CD140a expression of 
GFP+ gate (green) compared to CD45- cells (gray) c) Z-stack of PDGFRαKI H2B-
GFP lymph node imaged ex vivo using 2-photon microscopy. FRC nuclei (green), 
second harmonic signal (collagen) (blue). Wheat germ agglutinin AF647 (red) was 
injected subcutaneously 5 minutes prior to LN extraction to label conduits. Scale bar 
indicates 200 m. d) Immunohistochemical staining of paraffin embedded sections of 
LNs from PDGFRαKI H2B-GFP mice. Staining GFP (brown) and PDPN (pink), 
counterstained with haematoxylin (blue).  
Extended data Figure 8. Generation and characterisation of CD11cΔCLEC-2 mice. 
a) Scheme of targeting approach to allow conditional deletion of Clec1b exons 2,3, 
and 4. loxP sites shown in yellow. b) Clec1b mRNA in LPS-treated BMDC or freshly 
isolated CD11c+ splenocytes from CD11cΔCLEC-2 mice and Creneg littermates. Data 
are represented as relative expression compared to control and depict mean ± SD 
from 6 replicates from 2 independent experiments. p values calculated using 
Students’s t test. c) Quantification of bone marrow derived DC morphology cultured 
in contact with FRCs. Data indicate score of perimeter2/4πarea, area and perimeter 
calculated from immunofluorescence imaging using ImageJ software. Higher scores 
indicate increased elongation and/or protrusions. p=0.0007 calculated using Mann 
Whitney U test. d) Representative images from (c) showing DCs spreading over 
FRCs. F-actin (red), cell nuclei (blue). e) Total DC numbers and f) total FRC 
numbers in steady state skin-draining LNs of control vs CD11cΔCLEC-2 mice. Each 
data point represents one lymph node. g) PDPN surface expression by FRC from 
control and CD11cΔCLEC-2 mice as measured by flow cytometry and represented 
relative to the control group. MFI, mean fluorescence intensity. 
Extended Data Video 1 
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Confocal (20x objective) timelapse imaging showing the expression of PDPN-CFP 
(green) and ezrin-cherry (red) in NIH/3T3 fibroblasts. Imaging starts 16 hours after 
transfection. Acquisition rate 1 frame per 2 minutes. 
Extended Data Video 2 
Confocal (63x objective) timelapse imaging of FRCs stably expressing a RhoA 
biosensor. FRET ratio shown, red indicates highest and blue indicates lowest RhoA 
activity. Acquisition rate 1 frame per minute. CLEC-2-Fc beads were added after 10 
minutes. 
Extended Data Video 3 
Confocal (63x objective) timelapse imaging of FRCs stably expressing a Rac1 
biosensor. FRET ratio shown, red indicates highest and blue indicates lowest Rac1 
activity. Acquisition rate 1 frame per minute. CLEC-2-Fc beads were added after 10 
minutes. 
Extended Data Video 4 
Confocal (40x objective, 0.6 zoom) timelapse imaging of FRCs stably expressing 
GFP-MLC and treated with CLEC-2-Fc beads. Acquisition rate 1 frame/3 min. CLEC-
2-Fc beads were added from the beginning of acquisition. 
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Methods 
Mice 
Experiments were performed in accordance with national and institutional guidelines 
for animal care and approved by the Institutional Animal Ethics Committee Review 
Board, Cancer Research UK and the UK Home Office. Wild-type C57BL/6J mice 
were purchased from Charles River Laboratories (Wilmington, MA). PDGFRaKI-H2B-
GFP mice (B6.129S4-Pdgfratm11(EGFP)Sor/J) were purchased from Jackson 
laboratories. To generate Clec1b floxed mice on a C57BL/6 background, C57BL/6 
mouse clec1b genomic regions were cloned into a pFloxRI+TK targeting vector from 
the BAC clone R248K14 using the Red/Et recombination of Quick and Easy BAC 
modification kit (Gene Bridges, Dresden – Germany). Primers used were:  
Clec1b BAC Fwd  
TATTACCTGATGCTGTTACATCTCAGCTCTGCAGTATTTAGCCACCTTAGAGTTC
CTAGCTGCTGACTCTgggtaccgagctcgaattctaccg 
Clec1b BAC Rev 
(CTGGGTTCTTTCCAGCTTCTGGCTATTATAAATAAGGCTGTTATGAACATAGTG
GAGCATGTGTCCTTCTTgcggccgccaccgcggtggagctcca) 
Upper case represent regions homologous to clec1b regions and lower case 
represent regions homologous to pFloxRI+TK vector. PCR was performed using Pwo 
DNA polymerase (Roche) following the manufacturer’s instructions.  
The 5’ loxP site was introduced in the intronic region between exon 1 and exon 2 by 
insertion of the loxP-pgk-gb2-NEO-loxP cassette (Gene Bridges, Dresden – 
Germany) using the following primers: 
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1st loxP Fw 
AAAACCCAAAACCAAAAAACCAAAACCAACAACAAAACAAAAAAACAGATaattaac
cctcactaaagggcg 
1st loxP Rv 
ACTTATTCTCTGTCCATTCTAACATATAACTGGCTACCAAGGCCACGTGTtaatacg
actcactatagggctc 
Upper case represent regions homologous to clec1b regions and lower case 
represent regions homologous to loxP-pgk-gb2-NEO-loxP cassette. PCR was 
performed using Pwo DNA polymerase (Roche) following the manufacturer’s 
instructions. 
The vector was then transformed into CRE-expressing E. coli EL350 (kind gift from 
Axel Behrens) leading to recombination of the cassette and  leaving a single loxP 
site.  
Next, the FRT-pgk-gb2-NEO-FRT-loxP cassette was introduced into the intronic 
region between exon 4 and exon 5 using the following primers: 
Fw Rb2 
tcccatgtcaagcattttggaatgctgaggggaaacattgaaatgctgttaattaaccctcactaaagggc 
Rv Rb2 
tctcagaggagcacacagtgcaaaccattaagaaacacatgaaaaggaaataatacgactcactatagggctcg 
Upper case represent regions homologous to clec1b regions and lower case 
represent regions homologous to FRT-pgk-gb2-NEO-FRT-loxP cassette. PCR was 
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performed using Pwo DNA polymerase (Roche) following the manufacturer’s 
instructions. 
The targeting vector was linearised by SfiI digestion (New England Biolabs), 
precipitated by phenol/chloroform and electroporated into PRX-B6N C57BL/6N 
embryonic stem (ES) cells. 
Screening for homologous recombination in ES and mice was done by PCR using 
primers inside the FRT-pgk-gb2-NEO-FRT-loxP and outside the homology arm: 
C1b Gen Rv – agaccctgagaaggctgga 
NEO 3’ sense – gctcccgattcgcagcgcatc 
Deletion of the NEO cassette was performed by crossing Clec1b-targeted mice with 
βActin-Flp (B6.Cg-Tg(ACTFLPe)9205Dym), and thereafter generating Clec1blox/lox by 
interbreeding and screening for deletion of the NEO cassette using the following 
primers: 
Seq FRT Fw (cctggtaaggagggtcccat) and Seq FRT Rv (atgagtctgctagggatgct). 
Generation of CD11c∆CLEC-2 was achieved by crossing Clec1blox/lox with CD11c-Cre 
mice (B6.Cg-Tg(Itgax-cre)1.1Reiz; kind gift from Boris Reizis). Both males and 
females were used for in vivo experiments and were aged 8-12 weeks unless 
otherwise stated in figures. Cre negative littermates were used as controls in all 
experiments. 
qPCR analysis of Clec1b mRNA 
CD11c+ cells from day 9 cultures of bone marrow in GM-CSF (BMDC) and treated 
with LPS for 6h or from spleens were enriched by MACS using CD11c beads 
(Miltenyi). RNA was extracted using an RNeasy mini kit (Qiagen) and cDNA 
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generated using Superscript II reverse transcriptase (Invitrogen).  qPCR was carried 
out using Sybr Green comparing Clec1b expression to GAPDH in each sample. 
Primers for Clec1b: Forward – TTTGAGCACAAGTGCAGCCCC, Reverse – 
AAGCAGTTGGTCCACTCTTG. 
Constructs 
PDPN-CFP was as previously described8. RhoA and Rac-1 FRET biosensors were 
kindly provided by Michiyuki Matsuda. GFP-MLC was as previously described12. 
PDPN WT and mutants S167A and S167E were cloned into pcDNA3.1-V5-His by 
PCR using EcoR1 and Not-1 restriction sites.  
Cell lines 
NIH/3T3 fibroblasts were cultured in Dulbecco’s modified Eagle’s medium (DMEM) + 
glucose (Life Technologies, Invitrogen, CA, USA) with 10% fetal bovine serum (FBS) 
and penicillin and streptomycin (PS). Cells were incubated and maintained at 37oC in 
5% CO2. Mouse LN FRC lines were generated by first digesting skin-draining lymph 
nodes from C57BL/6 mice and then culturing adherent stromal cells as previously 
reported8. On day 4, stromal cells were immortalised by infection with HPV-E6-
encoding retrovirus and selected with 2.5 μM puromycin as for the generation of 
carcinoma-associated fibroblast cell lines26. Immortalised FRCs were isolated by 
sequential MACS depletion of CD45+ and CD31+ cells using biotin conjugated 
antibodies and anti-biotin beads (Mitenyi). FRC cell lines and maintained in DMEM + 
glucose (Life Technologies, Invitrogen, CA, USA) with 10% FBS, 
penicillin/streptomycin and 1% Insulin-Transferrin-Selenium (Life Technologies, 
Invitrogen, CA, USA) at 37oC in 5% CO2, and split using cell dissociation buffer (Life 
Technologies, Invitrogen, CA, USA). Stable knockdown of PDPN in FRCs was 
achieved with 2 different shRNA lentiviruses obtained from The RNAi Consortium of 
the Broad Institute (Cambridge, USA) that targeted the following sequences: 
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GCTGCATCTTTCTGGATAATA (PDPN KD1) and GTTCTCCCAACACATCTGAAA 
(PDPN KD2).  FRC cell lines expressing RhoA or Rac1 biosensors were generated 
by cotransfection of the biosensor plasmid with PiggyBac transferase using 
lipofectamine 2000, followed by selection with 5 μM blasticidin for 2 weeks. GFP-
MLC expressing FRC cell lines were generated by lentiviral transduction and cell 
sorting. All cell lines were regularly tested for absence of mycoplasma contamination 
by the Cell Services Laboratory, Cancer Research UK London Research institute. 
Over-expression studies 
NIH/3T3 cells were plated at a density of 50,000 cells/ml in a glass-bottomed 24 well 
plate (MatTek, MA, USA) the day before transfection with plasmids encoding GFP, 
PDPN-CFP or PDPN-V5-his using Effectene transfection reagent (Qiagen, Hilden, 
Germany) as per supplier’s instructions. After 24 hours, cells were treated with 
chemical inhibitors at the concentrations indicated (see Extended data Fig. 1b) for 6 
hours before fixation. CLEC-2-Fc was added at 10 µg/ml for the time indicated in 
figures before fixation. In cotransfection experiments, plasmids encoding PDPN-CFP 
and ezrin-Cherry or PDPN-V5-his and CD44-GFP were added in equal amounts to 
the transfection mix. The cells were analysed by fluorescence microscope (20X, 
Nikon Eclipse Te2000-S, Tokyo, Japan) and contraction status scored manually. 
Cells were grouped into either contracted, partially contracted, spread or collapsed, 
depending on their morphology. High-resolution images were taken using a confocal 
microscope (Zeiss 710 using a 20x/0.8NA objective). 
Immunofluorescence staining 
Cells were fixed with 4% paraformaldehyde (PFA) in PBS for 10 minutes before 
permeabilisation in PBS containing 0.2% Triton-X for 10 minutes at room 
temperature. The cells were stained with DAPI (Sigma, d9542, MO, USA) to reveal 
DNA in cell nuclei and TRITC-phalloidin (Sigma, p1951, MO, USA) to reveal F-actin 
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in 3% bovine serum albumin with PBS + 0.1% Tween-20. Cells were stained using 
anti-pMLC (S19) (Cell signaling technology #3675) or anti-pERM antibody (Cell 
signaling technology #3141) followed by appropriate Alexafluor-conjugated 
secondary antibodies (Invitrogen). PDPN-V5 was stained using anti-V5 FITC-
conjugated antibody (Invitrogen R963-25). ARP2/3 was stained using Anti-p34-
Arc/ARPC2 antibody (07–227 Millipore). 
Lipid raft colocalisation analysis 
Lipid raft labelling was carried out on ice on unfixed cells according to manufacturer’s 
instructions (Vybrant lipid raft labelling kit 555, Invitrogen). Cells were then fixed in 
4% paraformaldehyde before staining for PDPN (8.1.1 AF660-conjugated 
(eBioscience 50-5381-80). Confocal immunofluorescence images (63x/1.4NA oil 
immersion objective) of FRCs plated on glass either untreated or treated with 10 
μg/ml CLEC-2-Fc for 30 minutes prior to staining were analysed using Zen image 
analysis software (Zeiss). Correlation coefficient R was calculated based on pixel 
intensity. 
CLEC-2-Fc treatment in vitro 
Generation of CLEC-2-Fc was as previously described8. Soluble CLEC-2 was used 
at 10 μg/ml diluted in cell culture medium. For CLEC-2-beads, 10 μm protein A-
coated microspheres (Bangs laboratories) were incubated with 100 μg/ml CLEC-2-Fc 
diluted in PBS for 1 hour at 4°C then washed with cell culture medium. CLEC-2-Fc or 
CLEC-2-beads were added for the time indicated in the figures before fixation.  
Lymph node expansion in vivo 
Mice were immunised with 100 μl of an emulsion of OVA in CFA (100 µg OVA per 
mouse) or PBS in IFA subcutaneously in the right flank. Draining inguinal lymph 
nodes were taken for analysis at the indicated days post-immunisation; left-side non-
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draining lymph nodes were taken for comparison. Where mice were treated with 
CLEC-2-Fc, they received 10 μl (1 μg in PBS) subcutaneously adjacent to site of 
immunisation on days 1 and 3. Lymph nodes were first weighed, then digested as 
previously described27. Cells were counted and stained for flow cytometry analysis. 
Alternatively, intact lymph nodes were fixed in 10% formalin for 
immunohistochemistry analysis. 
Lymph node deformation assay 
Draining and non-draining inguinal lymph nodes were taken from CD11cΔCLEC-2 mice 
and littermate controls on day 5 following CFA immunisation. Lymph nodes were 
placed on the contact points of a digimatic thickness gauge (Mitutoyo, USA) and 
subjected to 1.4N of applied force. Deformability was calculated as follows: 
Deformability = 1 – (LN size under 1.4N/LN size before force was applied). Each LN 
was measured twice and the results averaged. 
Flow cytometry 
Cells isolated from LNs, FRCs or NIH/3T3 cell lines were suspended in FACS buffer 
(PBS 2% FCS, 2mM EDTA) and first blocked with anti-CD16/CD32 (eBioscience) for 
all staining procedures. Cells were counted on a FACS Calibur by reference to 
fluorescence beads. Stained cells were analysed on either a FACS Calibur or LSRII. 
Antibodies used for staining: CD45.1 (BD Biosciences), CD140a (clone APA5 
eBioscience), CD31 (BD Biosciences), PDPN (clone 8.1.1 eBioscience), CD35 
(clone 8C12 BD Biosciences), VCAM-1 (clone M/K-2 Abcam), CD44 (clone IM7 BD 
Biosciences), CD3 (BD Biosciences), CD19 (clone ID3 BD Biosciences), MHCII (I-
A/I-E BD Biosciences), CD11c (clone HL3 BD Biosciences).  
Immunohistochemistry 
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Tissue sections 4 µm thick were cut at 3 levels (with 150µm between the levels) from 
formalin-fixed paraffin-embedded lymph nodes. These sections were then stained 
using the Vector ABC elite detection system (PK6100 1:250,Vector laboratories, UK). 
Slides were first incubated with a primary antibody for 1 hour (anti-GFP: AB6673 
1:350, Abcam, anti-PDPN: DM3501, Acris), followed by incubation with biotinylated-
labelled secondary antibody (1:250, Vector laboratories, UK) for 45 min. ABC 
complex was then applied for 30 minutes and staining was completed by 3 min 
incubation with DAB and chromogen (SK 4100 Vector laboratories, UK). Slides were 
counterstained with hematoxylin and mounted. ER-TR7 staining was conducted on 
10 µm thick frozen LN sections (Santa Cruz sc-73355-AF488) 
Gap analysis  
Quantification of gap sizes was carried out in MATLAB. PDPN signal was isolated 
and converted to grayscale. The images were thresholded, background subtracted, 
small objects removed, then converted to binary images using ImageJ software. A 
circle-fitting algorithm was applied whereby, in each step, the largest circle that could 
fit in the gaps and that did not overlap with other fitted circles was recorded. The 
distribution of radii of circles that fill the image was then weighted according to area 
such that larger circles had a proportionally greater weighting than smaller circles. 
The plot of distribution of radii was smoothed to transform the data from a discrete 
pixel size distribution to a continuous micron size distribution. Raw data were 
analysed using Fisher’s exact test (p = 4.194e-09) to determine differences in circles 
with radius >15 μm. Each analysis was performed on images of the FRC network 
from >8 individual mice per group. No images were excluded from the analysis and 
all data were combined and are represented in the graphs shown (16 images per 
group). MATLAB script is available upon request. 
Automated Morphometric analysis 
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The slides were digitised with a commercial image analysis system (Ariol; Leica 
Biosystems). The program was trained to recognise GFP+ stained nuclei by size, 
shape and staining intensity. T cell areas were identified by density of hematoxylin 
staining and traced out manually on each lymph node in the scan. Automated 
analysis then counted the total number of GFP+ nuclei in each T cell area, (24 areas 
analysed per group). Area/FRC nuclei were compared using Mann Whitney U test. 
Rac1GTP pulldown assay 
FRC cell lines either treated with CLEC-2-Fc for 30 minutes or stably depleted of 
PDPN (shRNA) were subjected to Rac1 pulldown and analysis as per manufacturer’s 
instructions (kit 16118 Pierce). Rac-1 levels in pulldowns and whole lysate were 
compared by Western blot.  
3D cell culture and gel contraction assay 
Control or PDPN KD FRCs were seeded at 10,000 per well in 150 μl 
collagen/matrigel matrix8,26,28. Gels were set at 37°C for 30 minutes then covered with 
cell culture medium. In some wells, the following were added to both the gel mix and 
medium: 10 μg/ml CLEC-2-Fc, 10 μM ROCK inhibitor (Y27632) or 10 μg/ml anti-
PDPN antibody (R&D, AF3244). Contraction of the gel at day 3 was quantified as the 
ratio of contracted gel/original area and plotted relative to control. Gels were stained 
with TRITC-labelled phalloidin and DAPI for maximum length analysis (Imaris). The 
furthest points of each individual cell were measured in x,y,z coordinates and vectors 
calculated for comparison (Extended data figure 5). 
Statistics 
Sample size for in vivo experiments was determined by litter size as littermate 
controls were used in all comparisons. For in vitro experiments, all cells within the 
sample were scored and none excluded and experiments were repeated at least 
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once to ensure reproducibility and adequate statistical power. Category data from 
over-expression studies was analysed using Fisher’s exact test (R software). 
Changes to contraction and morphology were analysed using Mann Whitney-U tests. 
Analysis of cell populations during a time course of immunisation was conducted with 
one-way ANOVA and followed by Kruskall-Wallis multiple comparisons test. 
Comparison of LN size and cellularity between control and CD11cΔCLEC-2 across 
different treatment groups was analysed using 2-way ANOVA followed by multiple 
comparisons test between treatments and genotypes. Appropriate statistical tests 
were chosen for the data set following advice from a mathematician (R.P.J.). 
Chemical screen for cell contraction inhibitors was scored by an independent 
observer (A.F.) who was unbiased as to the predicted results. 
